JP2018517704A5 - - Google Patents

Download PDF

Info

Publication number
JP2018517704A5
JP2018517704A5 JP2017562664A JP2017562664A JP2018517704A5 JP 2018517704 A5 JP2018517704 A5 JP 2018517704A5 JP 2017562664 A JP2017562664 A JP 2017562664A JP 2017562664 A JP2017562664 A JP 2017562664A JP 2018517704 A5 JP2018517704 A5 JP 2018517704A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
composition
mir
nucleotide
oligonucleotide inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017562664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018517704A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/035794 external-priority patent/WO2016196978A1/en
Publication of JP2018517704A publication Critical patent/JP2018517704A/ja
Publication of JP2018517704A5 publication Critical patent/JP2018517704A5/ja
Pending legal-status Critical Current

Links

JP2017562664A 2015-06-05 2016-06-03 筋萎縮性側索硬化症（ＡＬＳ）を処置するためのｍｉＲ−１５５阻害剤 Pending JP2018517704A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562171743P 2015-06-05 2015-06-05
US62/171,743 2015-06-05
PCT/US2016/035794 WO2016196978A1 (en) 2015-06-05 2016-06-03 Mir-155 inhibitors for treating amyotrophic lateral sclerosis (als)

Publications (2)

Publication Number Publication Date
JP2018517704A JP2018517704A (ja) 2018-07-05
JP2018517704A5 true JP2018517704A5 (https=) 2019-07-04

Family

ID=57442041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017562664A Pending JP2018517704A (ja) 2015-06-05 2016-06-03 筋萎縮性側索硬化症（ＡＬＳ）を処置するためのｍｉＲ−１５５阻害剤

Country Status (6)

Country Link
US (1) US20180161357A1 (https=)
EP (1) EP3303589A4 (https=)
JP (1) JP2018517704A (https=)
CN (1) CN107922947A (https=)
CA (1) CA2986913A1 (https=)
WO (1) WO2016196978A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10184151B2 (en) 2011-10-11 2019-01-22 The Brigham And Women's Hospital, Inc. Micrornas in neurodegenerative disorders
KR20190118688A (ko) 2015-06-05 2019-10-18 미라젠 세러퓨틱스 인코포레이티드 피부 t 세포 림프종(ctcl) 치료용 mir-155 억제제
US11957713B2 (en) 2016-10-14 2024-04-16 Children's Medical Center Corporation Compositions and methods for treating diseases and disorders of the central nervous system
CA3050690A1 (en) 2017-01-17 2018-07-26 Dana-Farber Cancer Institute, Inc. Compositions and methods for diagnosing and treating peroxisomal diseases
AU2018210853B2 (en) 2017-01-17 2023-09-28 Children's Medical Center Corporation Compositions and methods for treating lysosomal storage diseases and disorders
EP3773606A4 (en) * 2018-04-03 2021-12-08 Academia Sinica MIR-17 ~ 92 USEFUL AS A THERAPEUTIC OR DIAGNOSTIC TARGET FOR DEGENERATING DISEASES OF MOTOR MOTORCYCLES (MN)
CN112585280A (zh) * 2018-08-23 2021-03-30 罗氏创新中心哥本哈根有限公司 微小rna-134生物标志物
WO2021067613A1 (en) * 2019-10-01 2021-04-08 Children's Medical Center Corporation Compositions and methods for treating amyotrophic lateral sclerosis
CN114272378B (zh) * 2020-09-27 2023-06-23 四川大学华西医院 一种使cttnbp2nl功能缺失的试剂在制备治疗疾病的药物中的用途
CN112587662A (zh) * 2020-12-22 2021-04-02 上海市徐汇区中心医院 一种miR-155/PEA15信号通路抑制剂在病理性心脏重构药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101437942A (zh) * 2006-04-03 2009-05-20 桑塔里斯制药公司 包含抗微小rna反义寡核苷酸的药物组合物
EP2007888A2 (en) * 2006-04-03 2008-12-31 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2623599B1 (en) * 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Micromirs
CA2717792A1 (en) * 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
ES2581178T3 (es) * 2009-07-29 2016-09-01 Pharnext Nuevas herramientas de diagnóstico para enfermedad de Alzheimer
US10184151B2 (en) * 2011-10-11 2019-01-22 The Brigham And Women's Hospital, Inc. Micrornas in neurodegenerative disorders
WO2013134403A1 (en) * 2012-03-06 2013-09-12 The Washington University Method of treating neurodegenerative diseases with microrna regulators

Similar Documents

Publication Publication Date Title
JP2018517704A5 (https=)
US20190062740A1 (en) COMPOSITIONS AND METHODS OF USING piRNAS IN CANCER DIAGNOSTICS AND THERAPEUTICS
JP2017505623A5 (https=)
AU2012322788A1 (en) Micrornas in neurodegenerative disorders
JP2016502858A5 (https=)
US12203071B2 (en) Oligonucleotide agonists targeting progranulin
JP2016522674A5 (https=)
JP2015523854A5 (https=)
JP2017519766A5 (https=)
JP2018531600A5 (https=)
KR20180081616A (ko) 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
JP2021500016A5 (https=)
WO2017192662A2 (en) Methods for identifying treatment targets based on multiomics data
KR20170069262A (ko) Smad7 안티센스 올리고뉴클레오티드로 대상체를 치료하기 위한 방법 및 조성물
Saeed Lupus pathobiology based on genomics
JP2011515357A5 (https=)
Wu et al. Effect of miR-513a-5p on etoposide-stimulating B7-H1 expression in retinoblastoma cells
US20200407721A1 (en) Compounds of chemically modified oligonucleotides and methods of use thereof
JP2019523302A5 (https=)
JP6049143B2 (ja) オリゴヌクレオチド、グルココルチコイド感受性増強剤、医薬組成物、及び発現ベクター
JP2024515240A5 (https=)
IL300439A (en) Treatment of sepsis with PCSK9 and LDLR modulators
Sanchez et al. Characterization of frataxin gene network in Friedreich's ataxia fibroblasts using the RNA-Seq technique
ZHANG et al. Analysis of DNA methylation of CD79B in MDV-infected chicken spleen
Niyazova et al. Features of mir-466-3p binding sites in mRNA genes with different functions